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http://dx.doi.org/10.1016/j.kjms.201Abstract Hepatitis C virus (HCV) infection is one of the most important causes of cirrhosis
and hepatocellular carcinoma and has a tremendous impact on public health worldwide.
HCV is both hepatotropic and lymphotropic. Replication of HCV in diseased extrahepatic organs
and tissues may either trigger latent autoimmunity or induce autoimmune disorders. In addi-
tion to established liver injury, type 2 diabetes mellitus (T2DM) is an important feature of
extrahepatic metabolic disorders which is attributed to HCV infection. It also has some impact
on the disease activity, disease course, clinical outcomes, and treatment efficacy of antiviral
therapy. Previous experimental and clinical findings have highly suggested that HCV per se is
diabetogenic. The causeeeffect interaction between a common endocrine disorder and an
infectious disease is an important issue to elucidate. Although the precise mechanisms
whereby HCV infection leads to insulin resistance (IR) and glucose abnormalities are not
entirely clear, it differs from the usual pathogenesis of T2DM in those with non-HCV liver
diseases. This review initially highlights epidemiological and pathophysiological studies ad-
dressing the mutual link between chronic HCV infection (CHC) and T2DM. The characteristics
of glucose abnormalities in this special population are depicted from the current evidence. The
mutual roles of IR and CHC with respect to the prediction of treatment efficacy, how treatment
response affects IR, and the role of pancreatic beta cell function in the entire suite are dis-
cussed. With the rapid progression of antiviral therapy for CHC in the past decade, we have
also listed some points of future perspective in this issue.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.ry Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100, Tzyou 1st
om, waloch@kmu.edu.tw (W.-L. Chuang).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
2.11.001
62 J.-F. Huang et al.IntroductionFigure 1. Prevalence of T2DM among patients with different
etiologies of viral hepatitis. Anti-HCV Z hepatitis C virus
antibodies; HBsAg Z hepatitis B surface antigen;
HCVRNA Z hepatitis C virus RNA; NBNC Z neither HBsAg(þ)
nor anti-HCV(þ); T2DM Z type 2 diabetes mellitus.Hepatitis C virus (HCV) infection and type 2 diabetes mel-
litus (T2DM) are two major rising epidemics which repre-
sent tough challenges both to clinicians and to healthcare
systems in terms of diagnostic, therapeutic and economic
implications. In 2003, over 194 million people were diag-
nosed with diabetes worldwide, with 333 million individuals
predicted to be affected by 2025. These numbers, however,
do not include those with undiagnosed diabetes, a pop-
ulation that is currently estimated to represent over one-
quarter of the US population alone. Furthermore, HCV
infection currently affects 3% of the world population,
estimated at 170 million people worldwide, which will lead
to a substantial rise in the prevalence of chronic liver
disease, with great health and economic impacts.
The liver has long been regarded as the key player
manipulating the homeostasis of glucose metabolism. As
the largest reservoir of glucose, the liver’s role in glucose
metabolism draws much attention in patients with
advanced liver disease. Insulin resistance (IR) is therefore
a common feature of some liver diseases, especially at
advanced stages. Hepatic diabetes was recognized when
diabetes developed in patients who had advanced liver
cirrhosis or severe liver injury, in which overt fasting
hypoglycemia and/or postprandial hyperglycemia emerge
as a common phenomenon. However, the association
between T2DM and CHC is beyond the concept of hepatic
diabetes. Although type 1 DM has been observed in patients
who were treated with interferon (IFN), the majority of
HCV-related diabetes is T2DM.
Epidemiological view
The association between T2DM and CHC was first reported
in 1994 by Allison et al., who observed that the prevalence
of T2DM was significantly higher in those with HCV-related
cirrhosis than those with cirrhosis resulting from other liver
diseases [1]. The diagnosis of HCV infection and the iden-
tification of risk factors for HCV infection preceded the
diagnosis and/or onset of T2DM in anti-HCV(þ) diabetic
patients [2]. Generally, the prevalence of anti-HCV sero-
positivity in the T2DM population ranged from 1.8% to
12.1%, whereas T2DM developed in 14.5e33.0% of CHC
patients [1,3e9]. Different background in terms of
ethnicity, age, prevalence of T2DM, body mass index (BMI),
viral load and genotype may contribute to the divergent
results of the epidemiological observations.
Huang et al., in a community-based case-controlled
study composing serological and virological features of HCV
infection, further extended the observation that HCV
viremia, but not anti-HCV seropositivity alone, increased
the association with T2DM (Fig. 1). HCV viremia was the
most significant independent factor to be associated with
T2DM in their multivariate logistic analysis, followed by
well-established factors such as male gender, hypertension,
BMI and age. It may imply that a persistent and/or active
phase of HCV infection is associated with T2DM [10]. Wang
et al. also observed that the 7-year cumulative incidence of
those anti-HCV(þ) patients was nearly doubled compared
to those HBsAgþ and negative controls from a prospectivecommunity cohort aged 40 years or more without T2DM.
After stratification by age and BMI, the risk ratio for T2DM in
anti-HCV(þ) participants increased as age decreased and
BMI levels increased [11]. Taken together, a link between
CHC and T2DM has been supported by robust epidemiolog-
ical evidence [1,3,4,9,12]. T2DM represented one more
disease to be included in the list of established extrahe-
patic manifestations of HCV infection.
The relationship between T2DM and HCV genotypes
remains controversial [2,3,8,13]. Zignego et al. demon-
strated that HCV genotype-2a (G-2a) was specifically linked
with extrahepatic manifestations such as cryoglobulinemia
[14]. An association between G-2a infection and T2DM was
also shown [3]. Recently, a large-scale international
collaborative study [15] addressing the association between
IR and viral clearance in G-1, -2 and -3 patients showed that
IR was more common in patients with G-1 than with G-2/3
infection. Viral eradication was associated with a reduction
in IR in patients infected with G-1 but not in those with G-2/
3 infection, suggesting a causal relationship between G-1
infection and IR in vivo. However, inconsistent observations
have been shown in previous studies of different geographic
regions [10,16].Pathophysiological view
T2DM is a common endocrine disorder encompassing
multifactorial pathogenic mechanisms. These mechanisms
include resistance to the action of insulin, increased
hepatic glucose production, and a defect in insulin secre-
tion, all of which contribute to the development of overt
hyperglycemia [17]. As well as skeletal muscle and adipose
tissue, liver is the major target for the metabolic actions of
insulin. Insulin regulates glucose homeostasis by reducing
hepatic glucose output and by increasing the rate of
glucose uptake by skeletal muscle and adipose tissue.
Therefore IR is a common feature of advanced liver
diseases from various insults.
HCV has been shown to be a lymphotropic as well as
a hepatotropic virus [18]. Replication of HCV in diseased
Glucose abnormalities and HCV 63extrahepatic organs and tissues may have cytopathic
effects [19]. The precise biological mechanisms whereby
HCV infection leads to IR are not entirely clear. However, it
does not follow the fashions of advanced liver disease as
mentioned above. HCV may induce a Th1 lymphocyte
immune-mediated response which leads to activation of the
tumor necrosis factor (TNF)-a system and elevation of
interleukin-6 levels. A high TNF-a level was considered to
be one of the bases of IR, which act by disturbing tyrosine
phosphorylation of insulin receptor substrate (IRS)-1,
a central molecule of the insulin-signaling cascade. Mean-
while, HCV directly causes liver steatosis. All the above
events may precipitate the development of liver fibrosis.
TNF-a system activation, liver steatosis and fibrosis
contribute to the development of IR, which plays a pivotal
role in the development of subsequent metabolic events
[8]. Meanwhile, HCV-induced inflammatory changes may
subsequently lead to increased oxidative stress and
increased peroxidation, which evoke systemic inflamma-
tory responses (SIR) more often than other liver diseases
[20]. SIR triggered by HCV and/or its subsequent immune
cascades and cytokine storms may play a major role in the
related pathogenic mechanisms in terms of liver injury and
the unique extrahepatic manifestations (Fig. 2). SIR may
also contribute either directly or indirectly to the diseaseFigure 2. Possible pathogenic mechanisms leading to the develop
HCV triggers an immune cascade, mainly mediated by Th1 lymphoc
elevation of IL-6 levels. HCV directly leads to steatosis, particula
systemic inflammatory response and cytokine storms, which are po
IR. Fibrosis may be exacerbated by the development of IR, partly by
the development of subsequent metabolic events. With respect t
aiming to maintain glucose homeostasis and elevated serum insulin
pancreatic beta-cell hyperfunction and beta-cell exhaustion may d
factors (genetic predisposition, male, race, body mass index etc),
factors (genotype, viral load) is also involved into the complex c
6 Z interleukin-6; IR Z insulin resistance; MS Z metabolic syndrocourse, viral response, disease severity, and response to
antiviral treatment. Cytokine triggering, which interacts
with innate and/or adaptive immune responses, is one of
the major concealed players of the scenario.
Evidence showing a direct diabetogenic effect of HCV
per se came from previous experimental study showing that
the ability of insulin to lower the plasma glucose level was
impaired without gain in body weight at young age in HCV
core gene transgenic mice. HCV core-induced suppressor of
cytokine signalling 3 may promote proteosomal degradation
of IRS1 and IRS2 through ubiquitination, which may be
a unique mechanism of HCV-associated IR [21]. In a clinical
observation, an increase in fasting insulin level was asso-
ciated with the presence of serum HCV core protein, the
severity of hepatic fibrosis, and a decrease in expression of
IRS-1 and IRS-2 in patients with HCV infection. More severe
IR was present in noncirrhotic patients with HCV infection
than in patients with other liver diseases. In patients with
undetectable levels of HCV core, fasting insulin levels were
within the normal range. In contrast, in patients with
detectable levels of HCV core, fasting insulin levels were
increased [16]. Taken together, HCV core protein seems to
play a pivotal role in HCV-associated IR. The precise
mechanisms whereby HCV infection leads to IR and glucose
abnormalities may differ from the usual pathogenesis ofment of insulin resistance and subsequent metabolic disorders.
ytes. These lymphocytes increase the activation of TNF-a and
rly in those with genotype-3 infection. HCV may also induce
tentially fibrogenic factors. All the events increase the risk for
the activation of hepatic stellate cell. IR plays a pivotal role in
o the development of DM, pancreatic beta-cell hyperfunction
level is the main feature before overt DM occurs. The scene of
evelop in the initial stages of HCV infection. The milieu of host
environmental factors (sedentary lifestyle, diet etc) and viral
ontext. DM Z diabetes mellitus; HCV Z hepatitis C virus; IL-
me; TNF-a Z tumor necrosis factor-a.
Figure 3. Distribution of glucose abnormalities among CHC
patients before and after OGTT. CHC Z chronic hepatitis C
virus infection; OGTT Z 75-g oral glucose tolerance test;
PreDM Z prediabetes; SDM Z subclinical diabetes.
64 J.-F. Huang et al.T2DM in those with non-HCV liver diseases. HCV may induce
IR regardless of the severity of liver disease and IR may be
associated with severe hepatic fibrosis and contribute to
fibrotic progression [13,22e25]. There was also a dos-
eeresponse relationship between HCV RNA level and the
presence of IR, whilst IR was positively associated with the
severity of hepatic steatosis [26].
Clinical view
The role of the oral glucose tolerance test
T2DM is often present at least 4e7 years before diagnosis
[27]. Therefore, definitive diagnosis of glucose abnormali-
ties is an important issue because it allows attempts to
improve clinical outcomes, such as weight reduction and
lifestyle modification [28,29]. However, almost all T2DM
patients have experienced the prediabetic condition (i.e.,
impaired fasting glucose level (IFG) and/or impaired
glucose tolerance (IGT)) before a definite diagnosis of T2DM
is made. In addition to future DM development, the predi-
abetic condition (IFG and IGT) also carries a risk for
cardiovascular disease [30,31].
Generally and commonly, fasting plasma glucose (FPG)
level alone is used as a screening test for the diagnosis of
DM. However, this practice is based on the relative conve-
nience and lower cost of FPG compared with a 75-g oral
glucose tolerance test (OGTT) [32,33]. It was estimated
that 19.3e59.3% of glucose abnormalities remained unde-
tected using the current IFG criteria alone [34].
The same scenario exists in the link between glucose
abnormalities and HCV infection. Previous data linking HCV
infection and DM mainly focused on patients with overt DM.
A threefold increase in the prevalence of glucose abnor-
malities was observed in anti-HCV(þ) patients in compar-
ison with anti-HCV(e) patients. In addition, 18% more new
DM cases and 30% more new cases of IGTwere uncovered by
OGTT in anti-HCV(þ) patients, which were significantly
higher than those values in anti-HCV(e) patients [35].
Another more stringent case-control study from Taiwan
recruited 683 CHC patients and 515 sex- and age-matched
community-based controls. The prevalence of normogly-
cemia, IGT and T2DM in 683 CHC patients was 27.7%, 34.6%,
and 37.8%, respectively. OGTT was performed in 522 CHC
patients and 447 controls without known T2DM. Of note is
that 18.6% of CHC patients who readily met with DM criteria
were undiagnosed (Fig. 3). For those without known DM,
there was a 3.5-fold increase in the prevalence of glucose
abnormalities in CHC patients in comparison with controls
(Table 1). Further analysis demonstrated that for those
without known DM history, CHC patients had a higher risk of
DM and IGT than controls with an odds ratio of 3.3. For
those without known DM history and with normal FPG level,
CHC patients had a higher risk of DM and IGT than controls
with an odds ratio of 10.2 [36]. The studies implied that
CHC patients carried a high prevalence of glucose abnor-
malities and also suggested that determination of glucose
abnormalities by OGTT should be indicated. It might also be
suggested that different criteria are necessary for DM
diagnosis in patients with HCV infection, such as lower cut-
off levels for normoglycemia, prediabetes and DM.Glucose abnormalities affecting treatment efficacy
of CHC
The “gold standard” for IR assessment is the hyper-
insulinemiceeuglycemic clamp test. However, the difficulty
of the technique and its laborious nature much discourage
the wider use of the test. The Homeostatic Model Assess-
ment (HOMA), which has been used in large epidemiological
studies, offers an estimate of IR. HOMA has the advantage
of requiring only a single fasting plasma sample measured
for glucose and insulin. Nonetheless, the lack of standard-
ization of insulin assays and the difference of IR standard-
ization between countries may undermine the accuracy of
the measurements [37].
Combination therapy with pegylated IFN (PegIFN) and
ribavirin (RBV) has been recommended as standard of care
(SOC) for patients with HCV infection with favorable effi-
cacy [38e40]. It therefore provides a wide scope of view
addressing the correlation between HCV infection and IR.
Several clinical predictors of the sustained virologic
response (SVR) to combination therapy have been eluci-
dated. The viral factors include genotypes, pretreatment
viral load and on-treatment viral kinetics [38e40], whereas
the host factors constitute age, BMI, races, interleukin-28B
(IL-28B) polymorphisms etc. [40e42]. Glucose abnormalities
have also been suggested recently to be a risk factor for
nonresponse [43]. Patients with high HOMA-IR achieved
a significantly lower rate of SVR than those who with low IR
[43,44]. The significantly lower SVR rate in high HOMA-IR
patients compared to low HOMA-IR patients was observed
in G-1 patients but not in non-G-1 patients (Fig. 4). Of note
was that IR was associated with SVR, especially among
“difficult-to-treat” patients, i.e., the patients with G-1
infection and high pretreatment viral loads (>400,000 IU/
mL). Since IR is considered as a factor which can be modi-
fied and improved by various interventions, further
prospective studies will be valuable to evaluate whether
the effective approaches to improve IR before initiation of
the combination therapy for CHC can significantly increase
the SVR rate.
Table 1 Characteristics of CHC patients without known DM and controls and their glucose abnormalities validated by OGTT.
Characteristics Anti-HCV(e) controls Anti-HCV(þ) patients p Odds ratio, 95% CI
Patients, n 447 552
Age (yr) 50.5  13.7 52.0  12.4 NS
Male 222 (49.7) 268 (48.6) NS
Normoglycemia 289 (64.7) 189 (34.2) <0.001 0.29, 0.22e0.37
Prediabetes 145 (32.4) 236 (42.8) 0.001 1.56, 1.20e2.02
Subclinical DM 13 (2.9) 127 (23.0) <0.001 9.98, 5.55e17.9
Data are presented as n (%) or mean  SD. CHCZ chronic hepatitis C virus infection; DMZ diabetes mellitus; OGTTZ 75-g oral glucose
tolerance test; CI Z confidence interval; NS Z not significant.
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agents improves treatment outcomes is speculative.
Current data from clinical trials by adding pioglitazone or
metformin to SOC have proved to be disappointing [45,46].
This may suggest that the emergence of IR in CHC evolved
from the multifactorial, complex context encompassing
viral, host and environmental factors.
Treatment outcome affecting glucose
abnormalities
IFN has been used widely for CHC treatment for two
decades [40,47]. However, IFN is an integral player in
immunity and may exacerbate an existing autoimmune
tendency, which may subsequently precipitate immune-
mediated abnormalities [48]. Emergences of IR and subse-
quent DM have been demonstrated with IFN-based therapy,
although the mechanism remains to be clarified [48,49].
Therefore, the interplay between IFN-based antiviral
therapy and alteration of insulin sensitivity deserved to be
elucidated. Reduced IR and subsequent improved glucose
control after conventional IFN therapy was observed amongFigure 4. Sustained virological response rates to combina-
tion therapy with pegylated interferon-a and ribavirin among
chronic hepatitis C patients and stratified by HCV genotype 1b
and non-1b infection. The HOMA-IR was defined as high (>2.5
black bars) and low (62.5 white bars). HCVZ hepatitis C virus;
HOMA Z homeostasis model assessment; IR Z insulin resis-
tance; SVR Z sustained virological response.chronic hepatitis B or CHC patients [50]. Romero-Gomez
et al. showed that HOMA-IR decreased after treatment in
responders, whilst it remained unchanged in nonresponders
[46]. Kawaguchi et al. further demonstrated that clearance
of HCV improves IR, beta-cell function, and hepatic IRS1/2
expression by immunostaining, whilst there were no
significant changes in IR and beta-cell function after anti-
viral therapy in nonresponders and relapsers [51]. Recently,
results of the HALT-C study which recruited patients with
advanced fibrosis or more showed that on-treatment viro-
logical suppression correlated with reduction in HOMA-IR at
Week 24 [52]. Huang et al. further extended the observa-
tion in G-1 and -2 patients showing that there was no
significant decline of HOMA-IR even in responders. The
significant decline of HOMA-IR after treatment was
observed only in patients with high pretreatment HOMA-IR,
regardless of SVR achievement [53]. Recent study in a clin-
ical trial cohort of CHC patients showed that SVR was
independently associated with a reduction in IR in G-1 but
not G-2/3 patients. The results suggest a causal relationship
between specific genotype and IR [15]. The somewhat
discordant results may imply that the HOMA-IR with respect
to SVR may have been influenced by variables such as race,
age, genotypes, validation methods for diabetes, cut-off
value of IR, treatment adherence, and/or the presence of
liver steatosis. Since the mechanisms that are involved in
the emergence of IR are multifarious, further long-term
follow-up study is needed to elucidate them in this context.
In addition to hyperinsulinemia, pancreatic beta-cell
hyperfunction aiming to maintain glucose homeostasis and
elevated serum insulin level is the main feature of glucose
abnormalities. The scene is also common in HCV infection,
and insulin secretion is increased in the initial stages of HCV
infection to compensate for IR development in both
experimental and human studies. There was a significant
relief of beta-cell function in nondiabetic Taiwanese CHC
patients with adequate treatment adherence after PegIFN/
RBV combination therapy, particularly in responders [53].
There was no significant decline of HOMA-IR in responders.
The sequential change of beta-cell function might suggest
that beta-cell function recovered earlier than that of IR in
CHC patients receiving PegIFN/RBV combination therapy.
Interaction with IL-28B genetic polymorphism
Recently, studies based on genome-wide associated studies
(GWAS) have shown that single nucleotide polymorphisms
66 J.-F. Huang et al.(SNPs) at and/or near the IL28B gene, which encodes
interferon-l, play a critical role in the treatment efficacy
of HCV infection [54,55]. It has been considered to be the
most important host factor contributing to SVR. Therefore,
the interplay between IL28B polymorphism and IR and its
related outcomes after antiviral therapy in CHC patients
deserves to be elucidated.
Recent studies demonstrated that there was no signifi-
cant difference in IL28B genotype distribution according to
pretreatment IR [56,57]. IR may undermine the advantages
of a favorable IL28B polymorphism to achieve SVR in G-1
patients [57]. Huang et al. further confined the observation
among prediabetic CHC patients with excellent treatment
adherence whose hemoglobin A1c levels were 5.7e6.4%.
There was no significant association between IL28B gene
polymorphism and baseline IR across G-1 and -2 patients
[56]. However, discordant results were recently reported
from another European study showing that IR is more
common in carriers of the unfavorable allele of IL28B in G-1
and -4 nondiabetic patients [58].
However, no significant association was observed
between IL28B gene polymorphism and outcome of glucose
abnormalities 24 weeks after completion of treatment
(Fig. 5). Intriguingly, despite no statistical significance
being reached, the prevalence of a favorable gene poly-
morphism in patients who developed DM after therapy
tended to be lower than patients who remained as predi-
abetic and those who developed normoglycemia after
therapy. The real scenario between gene polymorphism and
IR in different phases of glucose abnormalities deserves to
be further evaluated in a long-term fashion.Future perspectives
Recently, direct-acting antiviral agents (DAA) are under
investigation, including protease inhibitors, RNA poly-
merase inhibitors, and nonstructure protein 5A and 5B
inhibitors. Currently, the triple therapy with the first-
generation protease inhibitors (PI) and SOC can increase
the SVR rates from 40% to 70% in naive patients, and fromFigure 5. The proportion of IL28B rs8099917 TT genotype
according to treatment outcomes of glucose metabolism in pre-
diabetic chronic hepatitis C patients. IL28BZ interleukin 28B.20% to 65% in treatment-experienced patients with G-1
infection [59,60]. The emergence of DAA provides another
window through which to view the interaction between
CHC and IR. In a pilot Phase Ib placebo-controlled study,
a cohort of treatment-naive G-1 patients received dano-
previr, a PI, for 14 days. Serum HCV RNA was in a close
parallel with HOMA-IR according to the pattern of virolog-
ical response. Besides the proof of the efficacy of the new
specific antiviral drugs to overcome IR, the results of this
study thus provide definitive evidence for the link between
HCV infection and IR [61].
Concordant findings from recent study demonstrated that
baseline IR was not predictive of virological response in
treatment-naive G-1 patients receiving another PI (telapre-
vir) plus PegIFN/RBV therapy. In addition, SVR was associ-
ated with improved IR. This implied that, in contrast with
PegIFN/RBV, DAA may overcome the potential negative
effect ofmetabolic factors and IR on treatment efficacy [61].
This growing evidence helps to elucidate the interaction
between IR and CHC. It may also help to clarify the under-
lying pathogenic mechanisms leading to IR in HCV infection.
However, management of IR mainly depends on both
pharmaceutical intervention and lifestyle modifications,
such as exercise, diet control and weight reduction.
Whether these interventions play a role in the disease course
and prognosis of CHC patients deserves to be elucidated.
Conclusion
Glucose abnormalities are characteristic in patients with
HCV infection. The development of IR leads to some impact
on the disease activity, disease course, clinical outcomes,
and treatment efficacy of current SOC. Enormous chal-
lenges for patient management have been raised in parallel
with the occurrence of glucose abnormalities. The precise
mechanisms which contribute to glucose abnormalities
have not been fully clarified. Inspiring data and studies
during past decades, however, have much enhanced our
knowledge of this unique link between a viral hepatitis
disease and a worldwide metabolic disorder. Particularly
with the rapid progression of new therapies for CHC in
recent years, the interaction between HCV infection and
glucose abnormalities will likely become clearer. Mean-
while, recent promising data based on investigation of host
epigenetics have greatly extended our understanding of the
impact of host susceptibility on the occurrence of IR in
CHC. Taken together, these recent advances shed great
light for the future exploration of glucose abnormalities in
HCV infection.
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